Literature DB >> 9431931

Past and present hepatitis G virus infections in areas where hepatitis C is highly endemic and those where it is not endemic.

E Tanaka1, M Tacke, M Kobayashi, Y Nakatsuji, K Kiyosawa, S Schmolke, A M Engel, G Hess, H J Alter.   

Abstract

We reported previously on an area in Japan where over 30% of the inhabitants were positive for hepatitis C virus (HCV) antibody. In the present study, clinical features of hepatitis G virus (HGV) infection in this area of high endemicity were compared to those in an area where HCV is not endemic. A total of 400 individuals were selected randomly from those who were medically screened for liver disease in 1993; 200 were from the high-endemicity area, and the other 200 were from the no-endemicity area. HGV RNA was measured by reverse transcription and PCR with primers in the 5' noncoding region. Antibody to HGV envelope protein E2 was measured by an enzyme-linked immunosorbent assay. Prevalence of any HGV marker in the high-endemicity area (32%) was significantly (P < 0.0001) higher than that in the no-endemicity area (6%); similar differences, 32% versus 3% (P < 0.0001), had been observed for HCV markers (HCV RNA and HCV antibody). In areas of both high and no endemicity, HCV markers were significantly more prevalent in individuals with any HGV marker than in those without HGV markers, and age-specific prevalence of HGV markers was distributed similarly to that of any HCV marker. Among possible routes of HGV transmission that were analyzed, folk medicine was significant in the high-endemicity area, but blood transfusion was the major route in the no-endemicity area. The rate of accompanying viremia in HGV infection (15%) was significantly lower than that in HCV infection (78%) (P < 0.0001). In conclusion, HGV infection was highly prevalent in the area of high HCV endemicity and was closely associated with HCV infection. HGV seemed to be transmitted via the practice of folk medicine as well as blood transfusion. HGV resulted in a chronic carrier state less frequently than did HCV.

Entities:  

Mesh:

Year:  1998        PMID: 9431931      PMCID: PMC124818     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Effect of hepatitis G virus infection on chronic hepatitis C.

Authors:  E Tanaka; H J Alter; Y Nakatsuji; J W Shih; J P Kim; A Matsumoto; M Kobayashi; K Kiyosawa
Journal:  Ann Intern Med       Date:  1996-11-01       Impact factor: 25.391

2.  Avoiding false positives with PCR.

Authors:  S Kwok; R Higuchi
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

3.  Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team.

Authors:  M J Alter; M Gallagher; T T Morris; L A Moyer; E L Meeks; K Krawczynski; J P Kim; H S Margolis
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245

4.  The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.

Authors:  H J Alter; Y Nakatsuji; J Melpolder; J Wages; R Wesley; J W Shih; J P Kim
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245

5.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

7.  GB virus-C/hepatitis G virus infection in an area endemic for viral hepatitis, chronic liver disease, and liver cancer.

Authors:  J H Kao; P J Chen; M Y Lai; W Chen; D P Liu; J T Wang; M C Shen; D S Chen
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

8.  Detection of antibodies to a putative hepatitis G virus envelope protein.

Authors:  M Tacke; K Kiyosawa; K Stark; V Schlueter; B Ofenloch-Haehnle; G Hess; A M Engel
Journal:  Lancet       Date:  1997-02-01       Impact factor: 79.321

9.  Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors.

Authors:  M Tacke; S Schmolke; V Schlueter; S Sauleda; J I Esteban; E Tanaka; K Kiyosawa; H J Alter; U Schmitt; G Hess; B Ofenloch-Haehnle; A M Engel
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

10.  Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker.

Authors:  T J Pilot-Matias; R J Carrick; P F Coleman; T P Leary; T K Surowy; J N Simons; A S Muerhoff; S L Buijk; M L Chalmers; G J Dawson; S M Desai; I K Mushahwar
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

View more
  6 in total

Review 1.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

2.  Application of next generation sequencing for the detection of human viral pathogens in clinical specimens.

Authors:  Jayme Parker; Jack Chen
Journal:  J Clin Virol       Date:  2016-11-22       Impact factor: 3.168

3.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

4.  Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences.

Authors:  N Furusyo; J Hayashi; I Ariyama; Y Sawayama; Y Etoh; S Kashiwagi
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

Review 5.  Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?

Authors:  Jack T Stapleton
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 6.  Hepatitis G virus.

Authors:  Vasiliy Ivanovich Reshetnyak; Tatiana Igorevna Karlovich; Ljudmila Urievna Ilchenko
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.